Kiora Pharmaceuticals has received approval for its drug treatment for Ocular Presentation of autoimmune diseases

Kiora Pharmaceuticals, specialises in ophthalmology, developing treatment therapies for eye diseases. They have received approval for their new drug, KIO-101, to enter a Phase 2 study. The drug therapy focuses on treating the Ocular Presentation of Rheumatoid Arthritis and additional autoimmune diseases. The drug is a DHODH inhibitor, administered through eye drops, to reduce T-cell proliferation and ongoing proinflammatory cytokine release. Around 3.43 million patients in the U.S. suffer from the immune diseases that KIO-101 targets, all are caused by ocular manifestations.

Eric Daniels, M.D., Chief Development Officer of Kiora said: “KIO-101 is a topical, patient-friendly eye drop with a proven mechanism of action in autoimmune diseases. Proof-of-concept has been established in previous ocular inflammation clinical studies for KIO-101. This drug has the potential to finally close the wide gap of untreated ocular disease in patients with common autoimmune diseases.”